Transient anti-cytokine autoantibodies superimpose the hyperinflammatory response in Kawasaki disease and multisystem inflammatory syndrome in children: a comparative cohort study on correlates of disease.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 16 02 2023
revised: 03 07 2023
accepted: 15 07 2023
medline: 18 9 2023
pubmed: 1 8 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

Children with SARS-CoV-2 related Multisystem Inflammatory Syndrome in Children (MIS-C) often present with clinical features that resemble Kawasaki disease (KD). Disease severity in adult COVID-19 is associated to the presence of anti-cytokine autoantibodies (ACAAs) against type I interferons. Similarly, ACAAs may be implicated in KD and MIS-C. Therefore, we explored the immunological response, presence of ACAAs and disease correlates in both disorders. Eighteen inflammatory plasma protein levels and seven ACAAs were measured in KD (n = 216) and MIS-C (n = 56) longitudinally by Luminex and/or ELISA. Levels (up to 1 year post-onset) of these proteins were related to clinical data and compared with healthy paediatric controls. ACAAs were found in both patient groups. The presence of ACAAs lagged behind the inflammatory plasma proteins and peaked in the subacute phase. ACAAs were mostly directed against IFN-γ (>80%) and were partially neutralising at best. KD presented with a higher variety of ACAAs than MIS-C. Increased levels of anti-IL-17A (P = 0·02) and anti-IL-22 (P = 0·01) were inversely associated with ICU admission in MIS-C. Except for CXCL10 in MIS-C (P = 0·002), inflammatory plasma proteins were elevated in both KD and MIS-C. Endothelial angiopoietin-2 levels were associated with coronary artery aneurysms in KD (P = 0·02); and sCD25 (P = 0·009), angiopoietin-2 (P = 0·001), soluble IL-33-receptor (ST2, P = 0·01) and CXCL10 (P = 0·02) with ICU admission in MIS-C. Markers of endothelial activation (E-selectin, angiopoietin-2), and innate and adaptive immune responses (macrophages [CD163, G-CSF], neutrophils [lipocalin-2], and T cells [IFN-γ, CXCL10, IL-6, IL-17]), are upregulated in KD and MIS-C. ACAAs were detected in both diseases and, although only partly neutralising, their transient presence and increased levels in non-ICU patients may suggest a dampening role on inflammation. The Kawasaki study is funded by the Dutch foundation Fonds Kind & Handicap and an anonymous donor. The sponsors had no role in the study design, analysis, or decision for publication.

Sections du résumé

BACKGROUND BACKGROUND
Children with SARS-CoV-2 related Multisystem Inflammatory Syndrome in Children (MIS-C) often present with clinical features that resemble Kawasaki disease (KD). Disease severity in adult COVID-19 is associated to the presence of anti-cytokine autoantibodies (ACAAs) against type I interferons. Similarly, ACAAs may be implicated in KD and MIS-C. Therefore, we explored the immunological response, presence of ACAAs and disease correlates in both disorders.
METHODS METHODS
Eighteen inflammatory plasma protein levels and seven ACAAs were measured in KD (n = 216) and MIS-C (n = 56) longitudinally by Luminex and/or ELISA. Levels (up to 1 year post-onset) of these proteins were related to clinical data and compared with healthy paediatric controls.
FINDINGS RESULTS
ACAAs were found in both patient groups. The presence of ACAAs lagged behind the inflammatory plasma proteins and peaked in the subacute phase. ACAAs were mostly directed against IFN-γ (>80%) and were partially neutralising at best. KD presented with a higher variety of ACAAs than MIS-C. Increased levels of anti-IL-17A (P = 0·02) and anti-IL-22 (P = 0·01) were inversely associated with ICU admission in MIS-C. Except for CXCL10 in MIS-C (P = 0·002), inflammatory plasma proteins were elevated in both KD and MIS-C. Endothelial angiopoietin-2 levels were associated with coronary artery aneurysms in KD (P = 0·02); and sCD25 (P = 0·009), angiopoietin-2 (P = 0·001), soluble IL-33-receptor (ST2, P = 0·01) and CXCL10 (P = 0·02) with ICU admission in MIS-C.
INTERPRETATION CONCLUSIONS
Markers of endothelial activation (E-selectin, angiopoietin-2), and innate and adaptive immune responses (macrophages [CD163, G-CSF], neutrophils [lipocalin-2], and T cells [IFN-γ, CXCL10, IL-6, IL-17]), are upregulated in KD and MIS-C. ACAAs were detected in both diseases and, although only partly neutralising, their transient presence and increased levels in non-ICU patients may suggest a dampening role on inflammation.
FUNDING BACKGROUND
The Kawasaki study is funded by the Dutch foundation Fonds Kind & Handicap and an anonymous donor. The sponsors had no role in the study design, analysis, or decision for publication.

Identifiants

pubmed: 37524002
pii: S2352-3964(23)00301-8
doi: 10.1016/j.ebiom.2023.104736
pmc: PMC10403726
pii:
doi:

Substances chimiques

Cytokines 0
Angiopoietin-2 0
Autoantibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104736

Investigateurs

T Hendriks (T)
M K Felderhof (MK)
N M Weggelaar (NM)
L Filippini (L)
L Rozendaal (L)
M Groeneweg (M)
R Nuboer (R)
M Bruijn (M)
K M Dolman (KM)
J G Noordzij (JG)
J P de Winter (JP)
A M Vlieger (AM)
F B Plötz (FB)
L C Delemarre (LC)

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests BK received a grant from Stichting CJ Vaillant and Innovation Impulse from the Amsterdam UMC. ET is an employee of Hycult Biotech. FLV received a HDM-FUN Horizon 2020 grant. The other authors have declared that no conflict of interest exists.

Auteurs

Stejara A Netea (SA)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands. Electronic address: s.a.netea@amsterdamumc.nl.

Giske Biesbroek (G)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands.

Diana van Stijn (D)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands.

Hanna Ijspeert (H)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

Caspar I van der Made (CI)

Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.

Machiel H Jansen (MH)

Department of Experimental Immunology, Amsterdam UMC, UvA, Amsterdam, the Netherlands.

Judy Geissler (J)

Department of Blood Cell Research, Sanquin Research Institute, UvA, Amsterdam, the Netherlands.

J M Merlijn van den Berg (JMM)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands.

Martijn van der Kuip (M)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands.

Mariken P Gruppen (MP)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands.

Dieneke Schonenberg-Meinema (D)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands.

Berber Kapitein (B)

Pediatric Intensive Care Unit, Emma Children's Hospital, Amsterdam UMC, UvA, Amsterdam, the Netherlands.

A M Marceline Tutu van Furth (AMMT)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands.

Sietse Q Nagelkerke (SQ)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

Dasja Pajkrt (D)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands.

Frans B Plötz (FB)

Department of Pediatrics, Tergooi Hospital, Hilversum, the Netherlands.

M E J Lisette den Boer (MEJL)

Department of Pediatrics, Medical Spectrum Twente (MST), Enschede, the Netherlands.

Gijs W Landman (GW)

Department of Internal Medicine, Gelre Hospital, Apeldoorn, the Netherlands.

Marlies A van Houten (MA)

Department of Pediatrics, Spaarne Hospital, Haarlem, the Netherlands.

Ines Goetschalckx (I)

Department of Blood Cell Research, Sanquin Research Institute, UvA, Amsterdam, the Netherlands.

Erik J M Toonen (EJM)

R&D Department, Hycult Biotechnology, Uden, the Netherlands.

Frank L van de Veerdonk (FL)

Department of Internal Medicine, Radboud Center for Infectious Diseases, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.

Irene M Kuipers (IM)

Pediatric Cardiology, Emma Children's Hospital, Amsterdam UMC, UvA, Amsterdam, the Netherlands.

Willem A Dik (WA)

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

Taco W Kuijpers (TW)

Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, the Netherlands; Department of Blood Cell Research, Sanquin Research Institute, UvA, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH